Relay Therapeutics, Inc. Cash and Restricted Cash
Relay Therapeutics, Inc. (RLAY) had Cash and Restricted Cash of $122.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $122.53M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $205.93M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85.35M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $93.82M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $122.53M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $205.93M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $85.35M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $93.82M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $116.20M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $95.66M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $126.41M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $154.48M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $136.83M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $155.57M 10-Q · filed 2025-05-05 |
| 2023-12-31 | $146.44M 10-K · filed 2026-02-26 |
| 2023-09-30 | $154.03M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $148.61M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $163.85M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $154.37M 10-K · filed 2026-02-26 |
| 2022-09-30 | $357.22M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $110.31M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $122.02M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $282.70M 10-K · filed 2025-02-26 |
| 2021-09-30 | $231.14M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $262.65M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $263.60M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $448.52M 10-K · filed 2024-02-22 |
| 2020-09-30 | $560.16M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $137.93M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $71.22M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $42.83M 10-K · filed 2023-02-23 |
| 2019-09-30 | $29.92M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $40.23M 10-Q · filed 2020-08-27 |
| 2018-12-31 | $422.38M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |